30 Apr, 2026
30 Apr, 2026
Neuroendocrine tumor symptoms are deceptive. These rare cancers originate from hormone-producing cells distributed across the gut, pancreas, and lungs, and because many NETs quietly release bioactive compounds into the bloodstream, the body's distress signals are easily mistaken for far more ordinary conditions.
Chronic flushing. Persistent diarrhea. Unexplained low blood sugar. Each of these, individually, points toward something far more common. Taken together, with the right clinical eye, they point toward a net.
Neuroendocrine tumors are malignancies arising from neuroendocrine cells, a specialized population that bridges hormonal signaling and nerve conduction across multiple organs. Because these cells exist throughout the gastrointestinal tract, pancreas, lungs, and appendix, NETs can emerge almost anywhere, which complicates both recognition and staging.
The most clinically meaningful distinction is functional status. See the table below.
| Feature | Functioning NETs | Non-Functioning NETs |
|---|---|---|
| Hormone Production | Active secretion | None or subclinical |
| Primary Symptoms | Flushing, diarrhea, hypoglycemia, wheezing | Mass effect: abdominal pain, obstruction |
| Diagnosis Clue | Elevated hormonal biomarkers | Incidental imaging discovery |
| Common Sites | Midgut, pancreas (insulinoma, gastrinoma) | Pancreas, rectum |
The "zebra" cancer label comes from a foundational teaching in clinical medicine: "When you hear hoofbeats, think horses, not zebras." Essentially, doctors are trained to chase common diagnoses first. In other words, zebras refer to rare findings, while horses refer to common findings.
NETs produce symptoms, such as episodic skin flushing, loose watery stools, and breathlessness, that map almost perfectly onto irritable bowel syndrome, perimenopause, and allergic asthma. The underlying NET is often overlooked while those conditions are treated instead, which is why NETs are called zebra cancers.
Neuroendocrine tumor symptoms depend heavily on tumor location and whether the tumor secretes hormones actively.
Carcinoid syndrome develops when a midgut NET spreads to the liver, allowing serotonin and other vasoactive compounds to bypass hepatic breakdown and flood the body. This syndrome feels like sudden waves of burning warmth spreading across the face and upper chest, sometimes accompanied by a blotchy red flush that lasts minutes.
The other cardinal feature is secretory diarrhea, which is physically different from typical diarrhea. The stools are watery, high-volume, and occur with minimal warning, driven by serotonin stimulating intestinal motility rather than food intolerance or infection.
Additional carcinoid syndrome signs include:
Pancreatic neuroendocrine tumors produce distinct hormonal syndromes depending on cell type. An insulinoma overproduces insulin, causing recurrent episodes of shakiness, sweating, and confusion tied to hypoglycemia. A gastrinoma floods the stomach with acid, producing treatment-resistant peptic ulcers (Zollinger-Ellison syndrome). A glucagonoma drives elevated blood glucose alongside a distinctive, migratory skin rash called necrolytic migratory erythema.
Important caveat: These symptoms do not confirm a NET. Irritable bowel syndrome, menopausal vasomotor flushes, reactive hypoglycemia, and peptic ulcer disease all overlap significantly. Any symptom pattern persisting beyond two to three weeks warrants proper medical evaluation.
Chromogranin A (CgA) is a storage protein co-released alongside hormones from neuroendocrine cells. Elevated serum CgA levels indicate NET presence, and serial measurements track how the tumor responds to treatment. For carcinoid tumors specifically, a 24-hour urinary collection measuring 5-HIAA (a serotonin metabolite) adds biochemical confirmation.
The Ga-68 DOTATATE PET scan exploits a biological fact: most NETs densely overexpress somatostatin receptors on their cell surfaces. A radiolabeled somatostatin analog, introduced intravenously, homes to those receptors and emits a detectable signal. The result is a precise whole-body tumor map, catching liver metastases, bone deposits, and nodal involvement that conventional CT routinely misses.
To confirm NET diagnosis and determine biological aggressiveness, pathologists analyze extracted tumor tissue and assign a Ki-67 proliferation index. Grade 1 tumors carry a Ki-67 below 3% (slow-growing and have a favorable prognosis). Grade 2 falls between 3% and 20%. Grade 3, above 20%, behaves aggressively and requires a markedly different treatment strategy. This single number shapes the entire treatment plan.
Peptide Receptor Radionuclide Therapy (PRRT) is an internally delivered, molecularly targeted treatment that couples a beta-emitting radioisotope, Lutetium-177, to a somatostatin analog carrier peptide. Think of it this way: the peptide acts as a biological GPS, locking onto somatostatin receptors overexpressed on NET cells. The Lu-177 payload then irradiates the tumor from within, causing irreparable DNA damage to cancer cells while sparing nearby healthy tissue.
PRRT is the current standard of care for somatostatin receptor-positive advanced NETs that are unresectable or have progressed despite long-acting somatostatin analogs (octreotide, lanreotide).
Our oncologists at HCG administer Lu-177 DOTATATE across four intravenous cycles, spaced approximately eight weeks apart, in a radiation-shielded inpatient suite. Renal-protective amino acid infusions run concurrently with each session to reduce kidney radiation exposure. Dosimetry planning tailors the radiation dose to each patient's receptor density and organ function, rather than following a universal protocol.
The important NETTER-1 trial showed that Lu-177 PRRT greatly increased the time patients with advanced midgut NETs lived without their disease getting worse, compared to objective radiological tumor shrinkage, which occurs in approximately 20–30% of patients; disease stabilization, preventing further spread, is seen in the majority of patients. Individual outcomes vary by tumor grade, receptor expression density, and liver function status.
Post-treatment recovery integrates nutritional, biochemical, and imaging-based follow-up.
A carcinoid syndrome diet that avoids serotonin-stimulating foods (alcohol, aged cheeses, and certain nuts) reduces flare frequency during the recovery period. Somatostatin analogs are continued between cycles to maintain hormonal control.
Serial Chromogranin A checks at six-week intervals provide an early biochemical signal of tumor response. Follow-up Ga-68 DOTATATE PET-CT at three and six months after completing all cycles quantifies receptor-level response before structural CT shows changes. Our psycho-oncology team provides structured emotional support throughout, recognizing that living with a rare cancer diagnosis carries a distinct psychological weight beyond the physical treatment itself.
For many patients, the next helpful step is understanding that a delayed diagnosis is not a failed one. NETs are genuinely difficult to catch early because their symptoms blend into an ocean of more familiar conditions. The clinical tools available in 2026, Ga-68 DOTATATE receptor imaging, Ki-67 grading, and Lu-177 PRRT, have substantially changed what advanced NET management looks like.
HCG Cancer Hospital brings together nuclear medicine, molecular imaging, surgical oncology, and dedicated NET care pathways under one coordinated roof, so patients can move from diagnosis to treatment without fragmented referrals. If you are navigating an unexplained symptom pattern or a recent NET diagnosis, our multidisciplinary team is available to guide the next step with clarity and precision.
Disclaimer:This information is intended to educate patients and caregivers. It does not replace professional medical advice. All treatment decisions should be made in consultation with a qualified doctor.
Feel free to reach out to us.
